Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 6/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | GPR17 | Q13304 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1493589 | 0.86 | HSD11B1 (0.57) | HSD11B1NPSR1KMT2ATP53LMNA | |
| SCHEMBL1493557 | 0.76 | HSD11B1 (0.48) | HSD11B1MAPTTP53LMNA | |
| SCHEMBL1493404 | 0.74 | HSD11B1 (0.64) | HSD11B1NPSR1MAPTTP53LMNA | |
| SCHEMBL1613166 | 0.74 | HSD11B1 (0.46) | HSD11B1MEN1KMT2ALMNA | |
| SCHEMBL6282045 | 0.73 | MEN1 (0.59) | NPSR1MEN1KMT2AMAPTTP53 | |
| SCHEMBL1493377 | 0.73 | HSD11B1 (0.74) | HSD11B1NPSR1MEN1KMT2AMAPT | |
| SCHEMBL28702022 | 0.70 | HDAC6 (0.41) | HSD11B1NPSR1 | |
| SCHEMBL10676622 | 0.69 | LMNA (0.55) | HSD11B1NPSR1MEN1KMT2AMAPT | |
| SCHEMBL28692281 | 0.67 | NAALAD2 (0.42) | HSD11B1 | |
| SCHEMBL14988768 | 0.67 | NPSR1 (0.57) | NPSR1MEN1KMT2AMAPTGPR17 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110086889-A1 | TETRAZOLE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-04-14 | — | — | US | disclosed |
| EP-2288603-A1 | TETRAZOLE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2011-03-02 | — | — | EP | disclosed |
| WO-2009150614-A1 | TETRAZOLE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2009-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110086889-A1 | TETRAZOLE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY1R | HSD11B1 1201/4885NPSR1 9/4885MEN1 683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.